Table 2. AXL is upregulated in human EGFR mutant NSCLC specimens from patients with acquired EGFR TKI resistance.
Clinical characteristics and expression of the indicated biomarkers in the 35 paired EGFR-mutant NSCLC specimens obtained from patients both prior to treatment and upon acquired resistance to treatment with either erlotinib or gefitinib (Median PFS= 18 months, range 7–59). NA= not enough tissue available for analysis. ACC= adenocarcinoma. NSC= non-small cell carcinoma. SqCC= squamous cell carcinoma. VIM = vimentin.
| ID | Age | Sex | Tumor type |
EGFR mutation |
TKI | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AXL | GAS6 |
EGFR T790M |
MET amp |
VIM | ||||||||
| Baseline | Resistance | Baseline | Resistance | |||||||||
| 1 | 49 | M | ACC | L858R | 0 | 3 | NA | NA | − | N | NA | gefitinib |
| 2 | 50 | M | ACC | Del19 | 0 | 3 | 0 | 3 | − | N | N | gefitinib |
| 3 | 80 | M | ACC | Del19 | 0 | 3 | 0 | 3 | + | N | N | gefitinib |
| 4 | 64 | F | ACC | L858R | 1 | 3 | NA | NA | − | N | N | gefitinib |
| 5 | 47 | F | NSC | Del19 | 0 | 2 | NA | NA | − | NA | N | gefitinib |
| 6 | 48 | F | ACC | L858R | 2 | 3 | 2 | 2 | − | N | N | gefitinib |
| 7 | 59 | F | NSC | Del19 | 0 | 3 | 1 | 0 | + | N | NA | erlotinib |
| 8 | 67 | F | NSC | Del19 | 0 | 1 | 0 | 0 | + | N | NA | erlotinib |
| 9 | 74 | M | ACC | Del19 | 1 | 3 | 0 | 3 | − | N | Y | erlotinib |
| 10 | 49 | F | ACC | L858R | 2 | 3 | 2 | 3 | − | N | N | gefinitib |
| 11 | 43 | M | NSC | Del19 | 2 | 3 | 0 | 3 | − | N | N | gefinitib |
| 12 | 56 | F | NSC | Del19 | 1 | 1 | 0 | 2 | − | N | N | erlotinib |
| 13 | 54 | F | ACC | Del19 | 3 | 3 | 0 | 3 | − | N | NA | gefitinib |
| 14 | 67 | M | ACC | Del19 | 3 | 3 | 0 | 2 | − | N | NA | gefitinib |
| 15 | 59 | M | ACC | Del19 | 3 | 3 | 0 | 1 | − | NA | Y | gefitinib |
| 16 | 50 | F | ACC | Del19 | 0 | 0 | NA | NA | NA | Y | NA | gefitinib |
| 17 | 76 | F | ACC | Del19 | 0 | 0 | 3 | 3 | NA | N | NA | gefitinib |
| 18 | 64 | F | SqCC | Del19 | 0 | 0 | 0 | 0 | + | Y | NA | gefitinib |
| 19 | 66 | F | ACC | L858R | 0 | 0 | 1 | 0 | − | N | NA | gefitinib |
| 20 | 54 | F | ACC | Del19 | 0 | 0 | 0 | 0 | − | N | NA | gefitinib |
| 21 | 67 | F | ACC | L858R | 0 | 0 | NA | NA | NA | NA | NA | gefitinib |
| 22 | 73 | F | ACC | L858R | 0 | 0 | 3 | 3 | − | N | NA | gefitinib |
| 23 | 58 | M | ACC | Del19 | 0 | 0 | NA | NA | + | Y | NA | gefitinib |
| 24 | 73 | F | ACC | L858R | 0 | 0 | 2 | 2 | + | Y | NA | gefitinib |
| 25 | 62 | F | ACC | Del19 | 0 | 0 | 3 | 3 | NA | Y | NA | gefitinib |
| 26 | 77 | M | ACC | L858R | 0 | 0 | NA | NA | NA | NA | NA | gefitinib |
| 27 | 72 | F | ACC | Del19 | 0 | 0 | 2 | 3 | − | N | NA | gefitinib |
| 28 | 51 | F | ACC | L858R | 0 | 0 | 0 | 0 | − | N | NA | gefitinib |
| 29 | 67 | M | ACC | L858R | 0 | 0 | 3 | 3 | + | N | NA | gefitinib |
| 30 | 63 | M | ACC | L858R | 0 | 0 | 3 | 0 | − | N | NA | gefitinib |
| 31 | 57 | F | ACC | Del19 | 0 | 0 | 0 | 0 | NA | N | NA | gefitinib |
| 32 | 71 | F | ACC | Del19 | 0 | 0 | 0 | 0 | NA | N | NA | gefitinib |
| 33 | 54 | F | ACC | Del19 | 0 | 0 | 0 | 0 | − | N | NA | gefitinib |
| 34 | 56 | F | NSC | Del19 | 0 | 0 | 1 | 0 | − | Y | NA | gefitinib |
| 35 | 54 | F | NSC | Del19 | 0 | 0 | 0 | 0 | + | N | NA | gefitinib |